Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions? John W. Stevens Current Opinion 20 June 2018 Pages: 1135 - 1141
Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Rachid RafiaAbdullah PandorRobert Cutting Review Article 28 March 2018 Pages: 1143 - 1151
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Angela StainthorpeJanette GreenhalghDaniel Palmer Review Article Open access 29 March 2018 Pages: 1153 - 1163
Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review Carlos E. Rodriguez-MartinezMonica P. Sossa-BriceñoJose A. Castro-Rodriguez Systematic Review 04 June 2018 Pages: 1165 - 1200
Costs of Invasive Meningococcal Disease: A Global Systematic Review Bing WangRenee SantoreneosHelen Marshall Systematic Review 09 June 2018 Pages: 1201 - 1222
Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations Luis HernandezMalinda O’DonnellMaarten Postma Systematic Review 03 July 2018 Pages: 1223 - 1252
Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis Jesse ElliottBláthnaid McCoyDoug Coyle Original Research Article 15 May 2018 Pages: 1253 - 1261
The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study José LealStefania ManettiJames Buchanan Original Research Article Open access 22 May 2018 Pages: 1263 - 1272
Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer Mahdi GharaibehAli McBrideIvo Abraham Original Research Article 09 June 2018 Pages: 1273 - 1284
Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany Afschin GandjourDennis A. Ostwald Original Research Article 27 July 2018 Pages: 1285 - 1296
Comment on: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial Baptiste LeurentManuel GomesJames Carpenter Letter to the Editor 10 August 2018 Pages: 1297 - 1297
